Kevin Bitterman, Director at Akero Therapeutics, Inc. (AKRO), bought 505,099 shares at $16.00 ($4.3M) on 2019-06-24, disclosed to the SEC on 2019-06-25.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 235,099 | $0 | 0.0% |
| 2 | $16.00 | 270,000 | $4.3M | 100.0% |
| Total | $8.55 avg | 505,099 | $4.3M | 100% |
| Filing → |
| IRON | SELL | 2026-09-03 | $4.4M | — | Filing → |
| IRON | SELL | 2025-12-18 | $69K | — | Filing → |
| IRON | SELL | 2025-12-16 | $33.1M | — | Filing → |